Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2013
11/20/2013CN102329246B Multiple-target-point tamibarotene derivatives, preparation method and purposes thereof
11/20/2013CN102311449B Application of gossypol derivative to preparing anti-tumor medicament
11/20/2013CN102284040B Composition medicament for treating tumor
11/20/2013CN102260352B Targeted interleukin fusion protein as well as preparation method thereof and application thereof
11/20/2013CN102143936B Platinum complex and medical compound containing same
11/20/2013CN102140471B Oligo-nucleic acid for suppressing tumor growth and application thereof
11/20/2013CN102131807B Pyrazolopyridine kinase inhibitors
11/20/2013CN102100915B Chlorambucil multi-targeting medicine carrying system and preparation method and application thereof
11/20/2013CN101983191B Oxim derivatives as hsp90 inhibitors
11/20/2013CN101896193B An agent for reducing a side effect of an anticancer drug
11/20/2013CN101812126B Novel HLA-A2 restrictive epitope polypeptide coming from hPEBP4 protein and application thereof
11/20/2013CN101797382B Anti-human progastrin polypeptide immune composition
11/20/2013CN101723932B Nitropyridine ethylenimine compound, medicinal composition, preparation method and application thereof
11/20/2013CN101677572B Method of manufacturing a ruthenium complex
11/20/2013CN101530607B Method for extracting gingerol type material from ginger with high efficiency
11/20/2013CN101506196B Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses
11/20/2013CN101481323B Benzo cyclohepten derivate, and preparation and medical use thereof
11/19/2013US8586775 Therapeutic compounds and methods of use
11/19/2013US8586762 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
11/19/2013US8586739 Heterocyclic compounds and their uses
11/19/2013US8586717 Method for the diagnosis and prognosis of malignant diseases
11/19/2013US8586605 Fused amino pyridine as HSP90 inhibitors
11/19/2013US8586601 Stable SNS-595 compositions and methods of preparation
11/19/2013US8586600 Heterocyclic compounds and uses thereof
11/19/2013US8586585 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
11/19/2013US8586580 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors
11/19/2013US8586576 Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
11/19/2013US8586566 Unsaturated heterocyclic derivatives
11/19/2013US8586556 Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
11/19/2013US8586555 Immunomodulatory compositions, formulations, and methods for use thereof
11/19/2013US8586545 Solid materials of {[(2S, 5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acid} and methods for obtaining them
11/19/2013US8586524 Modulators of pharmacological agents
11/19/2013US8586332 Method for producing oligopolysaccharides
11/19/2013US8586311 Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
11/19/2013US8586291 Mutations in the Bcr-Abl tyrosine kinase associated with resistance to ST1-571
11/19/2013US8586098 Loading of hydrophobic drugs into hydrophilic polymer delivery systems
11/19/2013US8586091 Pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-quinazolinamine
11/19/2013CA2771188C Passive solid tumor-targeted pectin-doxorubicin prodrug and preparation method thereof
11/19/2013CA2692922C Azaindole-indole coupled derivatives, preparation methods and uses thereof
11/19/2013CA2681267C Anti-angiogenic agents and methods of use
11/19/2013CA2640997C Doxorubicin formulations for anti-cancer use
11/19/2013CA2634073C Compositions comprising ingenol-3-angelate
11/19/2013CA2609572C A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of tnf.alpha. and a carrier protein
11/19/2013CA2609062C Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm
11/19/2013CA2591991C Triazolophthalazines
11/19/2013CA2570698C Bis(thio-hydrazide amide) salts for treatment of cancers
11/19/2013CA2559650C Sns-595 and methods of using the same
11/19/2013CA2447139C Specific binding proteins and uses thereof
11/14/2013WO2013170191A1 Methods of using antagonists of nad biosynthesis from nicotinamide
11/14/2013WO2013170182A1 Treating cancer with an hsp90 inhibitory compound
11/14/2013WO2013170159A1 Treating cancer with hsp90 inhibitory compounds
11/14/2013WO2013170115A1 Pyridazine and pyridine derivatives as nampt inhibitors
11/14/2013WO2013170113A1 Nampt inhibitors
11/14/2013WO2013170112A1 Nampt inhibitors
11/14/2013WO2013170071A1 Bi-functional short-hairpin rna (bi-shrna) specific for single-nucleotide kras mutations
11/14/2013WO2013170069A1 Medicament, method, and drug delivery device for treatment of ovarian cancer
11/14/2013WO2013170066A1 Peptides for the treatment of cancer
11/14/2013WO2013170020A2 Determining prostate cancer recurrence using polymorphisms in angiogenesis-related genes
11/14/2013WO2013169989A1 Method and compounds for inhibiting the mcm complex and their application in cancer treatment
11/14/2013WO2013169913A1 Predictors of patient response to interferon-a therapy
11/14/2013WO2013169858A1 Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
11/14/2013WO2013169829A2 Method of treating cancer
11/14/2013WO2013169648A1 Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
11/14/2013WO2013169386A1 Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
11/14/2013WO2013169361A1 Iron chelators as hiv-1 inhibitors
11/14/2013WO2013169339A1 Methods for determining a nucleotide sequence
11/14/2013WO2013169337A1 Polymer conjugates with a linker
11/14/2013WO2013169291A2 Method for inducing udp-glucuronosyltransferase activity using pterostilbene
11/14/2013WO2013169077A1 Composition for preventing or treating cachexia
11/14/2013WO2013168918A1 Anti-erbb2 antibody variants
11/14/2013WO2013168820A1 Anti-cxadr antibody
11/14/2013WO2013168096A1 Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies
11/14/2013WO2013168075A1 Hexadepsipeptide analogues as anticancer compounds
11/14/2013WO2013167992A1 Compositions and methods for the treatment of inflammatory disorders
11/14/2013WO2013167990A1 Compositions and methods for the treatment of depression
11/14/2013WO2013167909A1 Herpes simplex virus for the treatment of liver cancer
11/14/2013WO2013167782A1 Amphiphilic copolymers carrying alpha-tocopherol having antitumoural properties
11/14/2013WO2013167756A1 Radio-pharmaceutical complexes
11/14/2013WO2013167755A1 Radio-pharmaceutical complexes
11/14/2013WO2013167754A1 Radio-pharmaceutical complexes
11/14/2013WO2013167744A1 Rna products and uses thereof
11/14/2013WO2013167698A1 Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
11/14/2013WO2013167403A1 Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
11/14/2013WO2013166966A1 Polymorphs of flourine-containing deuterium-substituted omega-diphenylurea or salts thereof
11/14/2013WO2013166952A1 Substituted aminoquinazolines useful as kinases inhibitors
11/14/2013WO2013166944A1 Rtn4b-related polypeptide, and, preparation and applications thereof
11/14/2013WO2013166943A1 Rtn4b polypeptide, monoclonal antibody thereof, monoclonal antibody-producing hybridoma cell line, and, preparation and application thereof
11/14/2013WO2013166901A1 Application of (e)-nitrogen-(4-cinnamic amide butyl) benzamide in preparation of antineoplastic medicament
11/14/2013WO2013166833A1 Pharmaceutical composition containing human cyclooxygenase and doxorubicin or doxorubicin analogue, preparation method therefor and use thereof in preparing drugs
11/14/2013WO2013166618A1 PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
11/14/2013WO2013166604A1 Single-arm monovalent antibody constructs and uses thereof
11/14/2013WO2013166594A1 Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
11/14/2013WO2013166557A1 Methods for treating cachexia
11/14/2013WO2013166555A1 Methods of treating cancer using angiogenin or an angiogenin agonist
11/14/2013WO2013142253A3 TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-c]PYRIDINES
11/14/2013WO2013107839A3 Phospholipid compounds for use in skin cancer treatment
11/14/2013WO2012149608A8 Prenylated hydroxystilbenes
11/14/2013WO2012082470A8 The use anti-cxcl16 and anti-cxcr6 antibodies for the treatment or detecting cancer
11/14/2013US20130303606 Platinum compounds as treatment for cancers, and related methods, kits, and compositions
11/14/2013US20130303592 Treatment of Cancer by Inhibition of IGFBPs and Clusterin
1 ... 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 ... 2211